Literature DB >> 28891813

No evidence of HIV replication in children on antiretroviral therapy.

Gert U Van Zyl1, Mary Grace Katusiime1, Ann Wiegand2, William R McManus2, Michael J Bale2, Elias K Halvas3, Brian Luke4, Valerie F Boltz2, Jonathan Spindler2, Barbara Laughton5, Susan Engelbrecht1, John M Coffin6, Mark F Cotton5, Wei Shao4, John W Mellors3, Mary F Kearney2.   

Abstract

It remains controversial whether current antiretroviral therapy (ART) fully suppresses the cycles of HIV replication and viral evolution in vivo. If replication persists in sanctuary sites such as the lymph nodes, a high priority should be placed on improving ART regimes to target these sites. To investigate the question of ongoing viral replication on current ART regimens, we analyzed HIV populations in longitudinal samples from 10 HIV-1-infected children who initiated ART when viral diversity was low. Eight children started ART at less than ten months of age and showed suppression of plasma viremia for seven to nine years. Two children had uncontrolled viremia for fifteen and thirty months, respectively, before viremia suppression, and served as positive controls for HIV replication and evolution. These latter 2 children showed clear evidence of virus evolution, whereas multiple methods of analysis bore no evidence of virus evolution in any of the 8 children with viremia suppression on ART. Phylogenetic trees simulated with the recently reported evolutionary rate of HIV-1 on ART of 6 × 10-4 substitutions/site/month bore no resemblance to the observed data. Taken together, these data refute the concept that ongoing HIV replication is common with ART and is the major barrier to curing HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28891813      PMCID: PMC5617669          DOI: 10.1172/JCI94582

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

3.  A robust measure of HIV-1 population turnover within chronically infected individuals.

Authors:  G Achaz; S Palmer; M Kearney; F Maldarelli; J W Mellors; J M Coffin; J Wakeley
Journal:  Mol Biol Evol       Date:  2004-06-23       Impact factor: 16.240

4.  Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.

Authors:  Mary F Kearney; Ann Wiegand; Wei Shao; John M Coffin; John W Mellors; Michael Lederman; Rajesh T Gandhi; Brandon F Keele; Jonathan Z Li
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

5.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

6.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Authors:  Courtney V Fletcher; Kathryn Staskus; Stephen W Wietgrefe; Meghan Rothenberger; Cavan Reilly; Jeffrey G Chipman; Greg J Beilman; Alexander Khoruts; Ann Thorkelson; Thomas E Schmidt; Jodi Anderson; Katherine Perkey; Mario Stevenson; Alan S Perelson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

7.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

8.  Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.

Authors:  Deborah Persaud; Stuart C Ray; Joleen Kajdas; Aima Ahonkhai; George K Siberry; Kimberly Ferguson; Carrie Ziemniak; Thomas C Quinn; Joseph P Casazza; Steven Zeichner; Stephen J Gange; Douglas C Watson
Journal:  AIDS Res Hum Retroviruses       Date:  2007-03       Impact factor: 2.205

9.  Genetic characterization of HIV type 1 long terminal repeat following vertical transmission.

Authors:  Roshni Mehta; Rajesh Ramakrishnan; Katherine Doktor; Vasudha Sundaravaradan; Nafees Ahmad
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

10.  HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.

Authors:  Guillaume J Besson; Christina M Lalama; Ronald J Bosch; Rajesh T Gandhi; Margaret A Bedison; Evgenia Aga; Sharon A Riddler; Deborah K McMahon; Feiyu Hong; John W Mellors
Journal:  Clin Infect Dis       Date:  2014-07-29       Impact factor: 9.079

View more
  35 in total

1.  Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.

Authors:  Sarah B Joseph; Laura P Kincer; Natalie M Bowman; Chris Evans; Michael J Vinikoor; Christopher K Lippincott; Magnus Gisslén; Serena Spudich; Prema Menezes; Kevin Robertson; Nancie Archin; Angela Kashuba; Joseph J Eron; Richard W Price; Ronald Swanstrom
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

2.  HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy.

Authors:  William R McManus; Michael J Bale; Jonathan Spindler; Ann Wiegand; Andrew Musick; Sean C Patro; Michele D Sobolewski; Victoria K Musick; Elizabeth M Anderson; Joshua C Cyktor; Elias K Halvas; Wei Shao; Daria Wells; Xiaolin Wu; Brandon F Keele; Jeffrey M Milush; Rebecca Hoh; John W Mellors; Stephen H Hughes; Steven G Deeks; John M Coffin; Mary F Kearney
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

Review 3.  Review: HIV-1 phylogeny during suppressive antiretroviral therapy.

Authors:  Michael J Bale; Mary F Kearney
Journal:  Curr Opin HIV AIDS       Date:  2019-05       Impact factor: 4.283

Review 4.  Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Authors:  Yu Gao; John C Kraft; Danni Yu; Rodney J Y Ho
Journal:  Eur J Pharm Biopharm       Date:  2018-04-17       Impact factor: 5.571

Review 5.  On the Road to a HIV Cure: Moving Beyond Berlin and London.

Authors:  Nikolaus Jilg; Jonathan Z Li
Journal:  Infect Dis Clin North Am       Date:  2019-09       Impact factor: 5.982

6.  Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo.

Authors:  Francesco R Simonetti; Hao Zhang; Garshasb P Soroosh; Jiayi Duan; Kyle Rhodehouse; Alison L Hill; Subul A Beg; Kevin McCormick; Hayley E Raymond; Christopher L Nobles; John K Everett; Kyungyoon J Kwon; Jennifer A White; Jun Lai; Joseph B Margolick; Rebecca Hoh; Steven G Deeks; Frederic D Bushman; Janet D Siliciano; Robert F Siliciano
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

7.  Clones of infected cells arise early in HIV-infected individuals.

Authors:  John M Coffin; David W Wells; Jennifer M Zerbato; Joann D Kuruc; Shuang Guo; Brian T Luke; Joseph J Eron; Michael Bale; Jonathan Spindler; Francesco R Simonetti; Shawn Hill; Mary F Kearney; Frank Maldarelli; Xiaolin Wu; John W Mellors; Stephen H Hughes
Journal:  JCI Insight       Date:  2019-06-20

8.  Advances toward a cure for HIV: getting beyond n=2.

Authors:  Jonathan Li
Journal:  Top Antivir Med       Date:  2020-01

Review 9.  Barriers and strategies to achieve a cure for HIV.

Authors:  Matthew C Pitman; Jillian S Y Lau; James H McMahon; Sharon R Lewin
Journal:  Lancet HIV       Date:  2018-06       Impact factor: 12.767

Review 10.  Targeting the Latent Reservoir for HIV-1.

Authors:  Srona Sengupta; Robert F Siliciano
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.